Genprex Presents Preclinical Data Identifying TROP2 as a Potential Predictive Biomarker for Reqorsa® Gene Therapy in Lung Cancer
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Genprex (GNPX) presented preclinical data linking low TROP2 levels to initial resistance to Reqorsa in models of non-small cell lung cancer. At the 2026 EORTC-NCI-AACR Symposium in Barcelona, the company reported that approximately 50% of 10 cancer cell lines and 50% of 12 patient-derived tumor models showed initial resistance to delivery of the TUSC2 gene. Tumor biopsies taken before treatment from patients in a TUSC2 gene therapy trial supported the link between TROP2 levels and response.
In separate cell experiments, increasing TROP2 in cells with low levels increased treatment-induced cell death, while reducing or removing TROP2 in cells with high levels increased treatment sensitivity. Further clinical studies are needed to establish whether TROP2 predicts response to Reqorsa in patients.
Positive
- Minor pointTROP2 emerged as a potential marker of Reqorsa resistance across multiple preclinical lung cancer models
- Minor pointPretreatment tumor biopsies from a TUSC2 gene therapy trial supported the link between TROP2 levels and response
- Minor pointChanging TROP2 levels increased treatment-induced cell death in TROP2-low cells and treatment sensitivity in TROP2-high cells
Negative
- Minor pointInitial resistance to TUSC2 gene delivery occurred in approximately 50% of 10 cell lines and 50% of 12 patient-derived organoid models
- Minor point. Forward-looking: it has not happened yet and may not happen.TROP2's ability to predict Reqorsa response in patients still needs to be established in prospective clinical studies
Key Figures
- Cell-line resistance
- Approximately 50% of 10 cell lines
- Primary resistance to TUSC2 gene delivery
- Organoid-model resistance
- 50% of 12 patient-derived organoid models
- Primary resistance to TUSC2 gene delivery
Historical Context
-
Earlier announcement identified low TROP2-associated resistance and scheduled this same research for symposium presentation.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
predictive biomarker medical
nsclc medical
apoptosis medical
shRNA technical
CRISPR/Cas9 technical
AI-generated analysis. How Rhea-AI works. Not financial advice.
Data Presented at the 2026 EORTC-NCI-AACR Symposium Show TROP2 Levels May Help Predict Which Tumors Respond to Reqorsa® and Modulating TROP2 May Enhance Efficacy
"Identifying which patients are most likely to benefit from REQORSA is one of the most important steps we can take to advance precision oncology," said Ryan Confer, President and Chief Executive Officer of Genprex. "These data suggest that TROP2 may help us identify which patients will benefit the most from REQORSA. These findings were supported across cell lines, patient-derived organoids and tumor models and in pretreatment biopsies from patients in our clinical program. Additionally, we are encouraged to see that TROP2 may do more than predict patient response. Our collaborators found that modulating TROP2 levels changes how cancer cells responded to REQORSA. We look forward to continuing to explore how TROP2 could help inform patient selection, and even potentially enhance REQORSA treatment, in future studies."
The TUSC2 tumor suppressor protein expression is downregulated or absent in more than
Key findings from the research include:
- Low TROP2 expression associated with resistance: Approximately
50% of 10 NSCLC cell lines and50% of 12 patient derived organoid models evaluated showed primary resistance to TUSC2 gene delivery. Protein-expression analyses consistently identified low TROP2 expression as a marker associated with resistance across multiple preclinical models. - Supporting clinical evidence: Analysis of pretreatment tumor biopsies from patients enrolled in a TUSC2 gene therapy clinical trial supported the association between TROP2 expression and treatment response.
- TROP2 modulation influenced treatment sensitivity: Introducing TROP2 into TROP2-low NSCLC cells (H460 and H1299) significantly increased TUSC2-induced apoptosis, to levels similar to cells that naturally express high TROP2. Conversely, knocking down or knocking out TROP2 in TROP2-high cells (H358 and H322) using shRNA or CRISPR/Cas9 also significantly increased sensitivity to TUSC2 gene therapy.
Collectively, the findings identify TROP2 as a potential predictive biomarker for response to REQORSA and suggest that modulating TROP2 signaling may be a novel strategy to enhance the therapeutic efficacy of REQORSA in NSCLC. While these findings provide preclinical and supportive clinical evidence, additional research and prospective clinical evaluation will be required to establish TROP2's predictive utility in patients receiving REQORSA.
The aforementioned poster is has been made available on Genprex's website at https://www.genprex.com/investors/downloads/.
About Reqorsa® Gene Therapy
Reqorsa® (quaratusugene ozeplasmid), a gene therapy product, consists of a plasmid containing the TUSC2 gene encapsulated in non-viral lipid-based nanoparticles in a lipoplex form (the Company's Oncoprex® Delivery System), which has a positive charge. REQORSA is injected intravenously and specifically targets cancer cells. REQORSA is designed to deliver the functioning TUSC2 gene to negatively charged cancer cells while minimizing uptake by normal tissue. Laboratory studies conducted at MD Anderson show that the uptake of TUSC2 in tumor cells in vitro after REQORSA treatment was 10 to 33 times the uptake in normal cells.
About Genprex, Inc.
Genprex, Inc. is a clinical-stage gene therapy company focusing on developing innovative treatments designed to restore biological functions disrupted by disease. The Company's lead oncology program, Reqorsa® (quaratusugene ozeplasmid), a gene therapy product, is being developed for the treatment of lung cancer and is designed to deliver the TUSC2 tumor suppressor gene to help restore tumor-suppressive activity and address multiple pathways involved in cancer progression.
The Company's lead candidate, REQORSA, uses the systemic, non-viral ONCOPREX® Delivery System to deliver the TUSC2 tumor suppressor gene via a non-viral lipid-based nanoparticle. REQORSA is being evaluated in the Acclaim-1 and Acclaim-3 clinical trials for non-small cell lung cancer and small cell lung cancer, respectively. The U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to both lung cancer programs and Orphan Drug designation to the small cell lung cancer program.
Genprex is also advancing an earlier stage gene therapy program for diabetes, designed to restore insulin-producing capability through the expression of key pancreatic transcription factors. Across its programs, Genprex is focused on translating innovative gene therapy approaches into meaningful therapeutic advances for patients with significant unmet medical needs.
For more information, please visit https://www.genprex.com/, register for our Email Alerts and follow us on LinkedIn, X, and Facebook.
Cautionary Language Concerning Forward-Looking Statements
Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are made on the basis of the current beliefs, expectations and assumptions of management, are not guarantees of performance and are subject to significant risks and uncertainty. These forward-looking statements should, therefore, be considered in light of various important factors, including those set forth in Genprex's reports that it files from time to time with the Securities and Exchange Commission and which you should review, including those statements under "Item 1A – Risk Factors" in Genprex's Annual Report on Form 10-K for the year ended December 31, 2025.
Because forward-looking statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding: Genprex's ability to advance the clinical development, manufacturing and commercialization of its product candidates in accordance with projected timelines and specifications, including identifying TROP2 expression as a potential predictive biomarker of response to REQORSA in NSCLC which has the potential of delivering more effective, personalized treatment options; the timing and success of Genprex's clinical trials, its intended regulatory submissions and any resulting regulatory approvals; the effect of Genprex's product candidates, alone and in combination with other therapies, on cancer and diabetes; Genprex's future growth and financial status, including Genprex's ability to maintain compliance with the continued listing requirements of The Nasdaq Capital Market and to continue as a going concern and to obtain capital to meet its long-term liquidity needs on acceptable terms, or at all; Genprex's commercial and strategic partnerships, including those with its third party vendors, suppliers and manufacturers and their ability to successfully perform and scale up the manufacture of its product candidates; Genprex's intellectual property and licenses; and Genprex's current expectations, estimates, forecasts and projections about the industry and markets in which it operates.
These forward-looking statements should not be relied upon as predictions of future events and Genprex cannot assure you that the events or circumstances discussed or reflected in these statements will be achieved or will occur. If such forward-looking statements prove to be inaccurate, the inaccuracy may be material. You should not regard these statements as a representation or warranty by Genprex or any other person that Genprex will achieve its objectives and plans in any specified timeframe, or at all. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Genprex disclaims any obligation to publicly update or release any revisions to these forward-looking statements, whether as a result of new information, future events or otherwise, after the date of this press release or to reflect the occurrence of unanticipated events, except as required by law.
Genprex, Inc.
(877) 774-GNPX (4679)
GNPX Investor Relations Contact
Lisa DeScenza
ldescenza@lavoiegroup.com
GNPX Media Contact
Kalyn Dabbs
media@genprex.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/genprex-presents-preclinical-data-identifying-trop2-as-a-potential-predictive-biomarker-for-reqorsa-gene-therapy-in-lung-cancer-302944720.html
SOURCE Genprex, Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.